Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group

Open source

DOI: 10.1016/s1470-2045(24)00373-5
Published: 2024 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00373-5,
  title = {Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.},
  author = {Oliveira M and Rugo HS and Howell SJ and Dalenc F and Cortes J and Gomez HL and Hu X and Toi M and Jhaveri K and Krivorotko P and Loibl S and Morales Murillo S and Okera M and Nowecki Z and Park YH and Sohn JH and Tokunaga E and Yousef S and Zhukova L and Fulford M and Andrews H and Wadsworth I and D'Cruz C and Turner NC and CAPItello-291 study group},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00373-5},
  url = {https://doi.org/10.1016/s1470-2045(24)00373-5}
}

RIS

TY  - JOUR
TI  - Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
AU  - Oliveira M
AU  - Rugo HS
AU  - Howell SJ
AU  - Dalenc F
AU  - Cortes J
AU  - Gomez HL
AU  - Hu X
AU  - Toi M
AU  - Jhaveri K
AU  - Krivorotko P
AU  - Loibl S
AU  - Morales Murillo S
AU  - Okera M
AU  - Nowecki Z
AU  - Park YH
AU  - Sohn JH
AU  - Tokunaga E
AU  - Yousef S
AU  - Zhukova L
AU  - Fulford M
AU  - Andrews H
AU  - Wadsworth I
AU  - D'Cruz C
AU  - Turner NC
AU  - CAPItello-291 study group
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00373-5
UR  - https://doi.org/10.1016/s1470-2045(24)00373-5
ER  -

APA

M, O., HS, R., SJ, H., F, D., J, C., HL, G., X, H., M, T., K, J., P, K., S, L., S, M. M., M, O., Z, N., YH, P., JH, S., E, T., S, Y., L, Z., M, F., H, A., I, W., C, D., NC, T., & group, C. S. (2024). Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00373-5

Source records

pubmed · retrieved 2026-09-27T07:07:17.244Z
europe-pmc · retrieved 2026-09-27T07:07:17.238Z